Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension.
about
Treatment-related biomarkers in pulmonary hypertensionRoles of accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, and attenuated nitric oxide synthase activity in endothelial cells for pulmonary hypertension in ratsPulmonary arterial hypertension: the clinical syndrome.Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapiesDysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell diseaseNew strategies for the treatment of pulmonary hypertension in sickle cell disease : the rationale for arginine therapy.New perspectives for the treatment of pulmonary hypertensionDisruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertensionHemoglobin solutions and tissue oxygenation.Analysis of volatile compounds in exhaled breath condensate in patients with severe pulmonary arterial hypertension.Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.Safety of drug therapies used for weight loss and treatment of obesity.Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertensionPerinatal changes in superoxide generation in the ovine lung: Alterations associated with increased pulmonary blood flowEarly determinants of pulmonary vascular remodeling in animal models of complex congenital heart diseasePhosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension.Computer-aided (in silico) approaches in the mode-of-action analysis and safety assessment of ostarine and 4-methylamphetamine.Fenfluramine-induced gene dysregulation in human pulmonary artery smooth muscle and endothelial cellsDecreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension.Decreased pulmonary and tracheal smooth muscle expression and activity of type 1 nitric oxide synthase (nNOS) after ovalbumin immunization and multiple aerosol challenge in guinea pigs.Dexfenfluramine protects against pulmonary hypertension in rats.Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?Pulmonary and systemic nitric oxide measurements during CCK-5-induced panic attacks.Oxidative stress in severe pulmonary hypertension.Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy.Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients.Inhibition of nitric oxide synthase unmasks vigorous vasoconstriction in established pulmonary arterial hypertension.Fractional Exhaled Nitric Oxide Measurement in Pulmonary Hypertension: A Follow-Up Study.RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.Pulmonary Hypertension Is a Probable NO/ONOO− Cycle Disease: A Review
P2860
Q28081276-7178810C-B073-4A4C-BC19-8C3EE65F6B69Q28578942-EB8DD38D-6B95-4BEC-89CB-C17BEB5E3F89Q30583630-6AAC1EB6-51BC-47B4-AE32-85AABC82917CQ33849207-CF596439-73E2-4591-A151-412517C85070Q34431518-154CC90C-8A11-4D68-8747-C9A86CFD7358Q34484036-4B1AC613-E8B1-48BE-8622-1F1545D8E885Q34903204-2789C0FF-814E-410F-91B7-DA6C8B55B71AQ35040806-7D06A5BB-9769-4386-BBC1-D6536DF1AEA0Q35102628-A0C67A7D-28A8-41FE-93A9-E6E2326841AFQ35153029-B0FF7806-441F-4929-B970-7EAEE6187819Q35620058-408A5F13-3C3C-4BBA-96ED-398F51AE4B55Q36433990-3DC9AD33-C1C5-4BAE-8DDF-45E13EFCED84Q36943390-9127A237-27B9-4061-8AFF-98D515599BA4Q37274266-2376B348-E6E8-40B8-A58A-EA78EB939672Q37416218-BD51EF88-B3DA-4C77-9D71-92303E6BF4D7Q37600767-9F90FA29-69DA-4263-8617-EAD4E3436DF8Q38119018-A334869C-FBCE-4ABF-B4D3-F00A976C3FECQ39379084-D4B140F6-1CEA-4DAC-90C5-D316083D8320Q39385317-EF0D97D0-1169-4E6C-842B-5671BBF2CE8BQ42473334-84578D55-B554-4588-A99A-533EF3542003Q43660412-7AEEDC5C-469F-4F5E-81C5-DFFA37D3BD4BQ44180844-D3A85CB4-6A21-45FA-8C47-A6B5F4CD09E3Q44355177-1EDC5EC6-B5E2-4457-A056-A79EA9F0F28AQ44515041-9DB898E7-EC58-4972-9809-A5EAE6EA5F57Q44710488-DB2DB1B7-D835-4318-9AF3-3B89C4E08891Q46477675-9E125605-9859-48B4-A069-47859A25FDFDQ46829214-A253D31C-FAC7-4A3F-8148-65F33F3E254EQ47111545-A4AF5140-CA4F-4E2C-B44B-D164E8DD5E82Q47398434-989AF664-96B1-4AE7-8253-DBD8EB68AC82Q47687572-31C3E0EF-BE32-436A-9C14-B80837A8C187Q58998388-E0E03252-7C8B-4233-842B-1C379BCF5516
P2860
Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Nitric oxide deficiency in fen ...... nduced pulmonary hypertension.
@en
Nitric oxide deficiency in fen ...... nduced pulmonary hypertension.
@nl
type
label
Nitric oxide deficiency in fen ...... nduced pulmonary hypertension.
@en
Nitric oxide deficiency in fen ...... nduced pulmonary hypertension.
@nl
prefLabel
Nitric oxide deficiency in fen ...... nduced pulmonary hypertension.
@en
Nitric oxide deficiency in fen ...... nduced pulmonary hypertension.
@nl
P2093
P2860
P1476
Nitric oxide deficiency in fen ...... induced pulmonary hypertension
@en
P2093
A T Dinh-Xuan
G Simonneau
J C Mercier
J Dall'ava-Santucci
K Djaballah
M Fartoukh
S L Archer
P2860
P304
P356
10.1164/AJRCCM.158.4.9802113
P407
P50
P577
1998-10-01T00:00:00Z